Silence Therapeutics (SLN) Projected to Post Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN - Get Free Report) is projected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Silence Therapeutics to post earnings of ($0.16) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

Silence Therapeutics Stock Performance

Silence Therapeutics stock traded up $0.08 during mid-day trading on Monday, reaching $4.87. 116,121 shares of the company were exchanged, compared to its average volume of 337,212. The firm has a market cap of $149.64 million, a P/E ratio of -3.10 and a beta of 1.05. The business has a fifty day moving average of $5.78 and a 200 day moving average of $12.07. Silence Therapeutics has a 12-month low of $4.06 and a 12-month high of $27.72.

Analyst Upgrades and Downgrades

SLN has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, January 29th. Chardan Capital reissued a "buy" rating and set a $55.00 price target on shares of Silence Therapeutics in a research report on Tuesday, December 10th. William Blair reaffirmed an "outperform" rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. BMO Capital Markets reissued an "outperform" rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Finally, The Goldman Sachs Group started coverage on shares of Silence Therapeutics in a research note on Tuesday, February 11th. They issued a "sell" rating and a $6.00 target price for the company. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Silence Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.00.

Remove Ads

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.